BioSpace News Archive

Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the upcoming American Society of Genetic & Cell Therapy Annual Meeting held virtually May 11-14, 2021.

Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases

Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD)

Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier (GSC), a novel genomic test, in helping to improve lung cancer diagnosis.

Be The Match Day at the Capitol on April 27 Celebrates Yusuf’s Support for HB 780 and the Thousands of Texans Given a Second Chance at Life Through Marrow Transplant

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that it will report financial results for the three months ended March 31, 2021 on May 5, 2021 after the market close.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced that the Company will give six poster presentations at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11 – 14.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced preclinical data presentations from non-human primate (NHP) studies at two upcoming medical meetings, the American Society for Gene and Cell Therapy (ASGCT) 24th Annual Meeting,

Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced an oral presentation and three digital posters have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting